NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis $5.12 +0.02 (+0.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.09▼$5.2350-Day Range$4.02▼$7.3352-Week Range$2.23▼$8.95Volume93,984 shsAverage Volume364,190 shsMarket Capitalization$77.98 millionP/E RatioN/ADividend YieldN/APrice Target$41.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Affimed alerts: Email Address Affimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside713.8% Upside$41.67 Price TargetShort InterestHealthy7.46% of Float Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment1.26Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.60) to ($2.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.96 out of 5 starsMedical Sector213th out of 936 stocksPharmaceutical Preparations Industry88th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAffimed has only been the subject of 2 research reports in the past 90 days.Read more about Affimed's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.46% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently decreased by 2.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 2.9 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Affimed this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for AFMD on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions.Read more about Affimed's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($3.60) to ($2.27) per share.Price to Book Value per Share RatioAffimed has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Affimed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Affimed Stock (NASDAQ:AFMD)Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFMD Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 17, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Sees Significant Growth in Short InterestJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 12, 2024 | investorplace.comAFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024June 12, 2024 | globenewswire.comAffimed Reports First Quarter 2024 Financial Results & Business UpdateJune 5, 2024 | globenewswire.comAffimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024June 1, 2024 | globenewswire.comAffimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortMay 29, 2024 | msn.comAffimed gets FDA fast track status for AFM24 for EGFR lung cancerJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | markets.businessinsider.comAffimed's AFM24 With Atezolizumab For EGFR Wild-Type NSCLC Gets FDA Fast Track Status; Stock UpMay 29, 2024 | globenewswire.comAffimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerMay 28, 2024 | globenewswire.comAffimed Announces Annual General Meeting of ShareholdersMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 23, 2024 | globenewswire.comAffimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024May 17, 2024 | investorplace.comSmall-Cap Sensations: 3 Stocks Under $10 With 10X PotentialMay 14, 2024 | globenewswire.comAffimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressApril 24, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 24, 2024 | globenewswire.comAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologySee More Headlines Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/12/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$41.67 High Stock Price Target$70.00 Low Stock Price Target$10.00 Potential Upside/Downside+709.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,660,000.00 Net Margins-2,361.94% Pretax Margin-2,363.20% Return on Equity-135.81% Return on Assets-87.96% Debt Debt-to-Equity Ratio0.12 Current Ratio3.06 Quick Ratio3.06 Sales & Book Value Annual Sales$8.95 million Price / Sales8.76 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book1.23Miscellaneous Outstanding Shares15,230,000Free Float14,648,000Market Cap$78.43 million OptionableOptionable Beta2.12 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Andreas Harstrick M.D. (Age 63)Interim CEO, Chief Medical Officer & Member of Management Board Comp: $535.09kDr. Wolfgang Fischer (Age 60)MD, COO & Member of Management Board Comp: $645.58kMs. Denise Mueller (Age 54)Chief Business Officer & Member of Management Board Comp: $628.24kProf. Melvyn LittleFounder & ConsultantMr. Michael Wolf (Age 57)Head of Finance & Administration Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsMary Beth SandinVice President of Marketing & CommunicationsMore ExecutivesKey CompetitorsAurora CannabisNASDAQ:ACBSutro BiopharmaNASDAQ:STROEnanta PharmaceuticalsNASDAQ:ENTAAdaptimmune TherapeuticsNASDAQ:ADAPCartesian TherapeuticsNASDAQ:RNACView All CompetitorsInstitutional OwnershipKennedy Capital Management LLCSold 622,134 shares on 5/16/2024Ownership: 0.066%NEA Management Company LLCSold 3,983,839 shares on 5/15/2024Ownership: 2.906%Nan Fung Group Holdings LtdSold 335,225 shares on 5/14/2024Ownership: 0.245%BNP Paribas Financial MarketsSold 499,391 shares on 5/1/2024Ownership: 0.477%View All Institutional Transactions AFMD Stock Analysis - Frequently Asked Questions How have AFMD shares performed this year? Affimed's stock was trading at $6.25 at the start of the year. Since then, AFMD stock has decreased by 18.1% and is now trading at $5.12. View the best growth stocks for 2024 here. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) issued its earnings results on Wednesday, June, 12th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, topping the consensus estimate of ($1.73) by $0.35. The biopharmaceutical company earned $0.17 million during the quarter, compared to analyst estimates of $1.76 million. Affimed had a negative trailing twelve-month return on equity of 135.81% and a negative net margin of 2,361.94%. When did Affimed's stock split? Affimed's stock reverse split on the morning of Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Affimed's major shareholders? Affimed's top institutional shareholders include Concourse Financial Group Securities Inc.. How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX) and Amarin (AMRN). This page (NASDAQ:AFMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
